Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?

VOICE — a phase 2B, placebo-controlled, randomized trial testing daily use of an antiretroviral tablet (tenofovir or Truvada) or daily use of tenofovir gel in 5029 women from South Africa, Uganda, and Zimbabwe — found none of the drug regimens effective in reducing HIV-1 acquisition in the intent-to...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:AIDS Behav
Asıl Yazarlar: Mensch, Barbara S., Brown, Elizabeth R., Liu, Karen, Marrazzo, Jeanne, Chirenje, Zvavahera Mike, Gomez, Kailazarid, Piper, Jeanna, Patterson, Karen, van der Straten, Ariane
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2016
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5354168/
https://ncbi.nlm.nih.gov/pubmed/26906023
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10461-016-1312-2
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller